3 withdrawn, 1 completed. 2 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 2 | Withdrawn 2 |
| Early Phase 1 | 1 | Withdrawn 1 |
Follow Flame Biosciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FL- 101 Study in Non-Metastatic MIBC FL-101 - Muscle Invasive Bladder Carcinoma | Early Phase 1 | Withdrawn | Flame Biosciences | 2022-08-22 | 2022-08-19 | |
| Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors 1 mg/kg IV FL-301, 3 mg/kg IV FL-301, 10 mg/kg IV FL-301 - Pancreas Cancer, Gastric Cancer | Phase 1 / Phase 2 | Withdrawn | Flame Biosciences | 2022-01-01 | 2022-02-07 | |
| A Bioavailability Study of FL-101 in Healthy Male and Female Subjects FL-101-Intravenous, FL-101-Subcutaneous - Healthy Subjects | Phase 1 | Completed | Flame Biosciences | 24 | 2021-09-11 | 2022-06-01 |
| FL-101 in Surgically Resectable Non-Small Cell Lung Cancer FL-101, Nivolumab, Placebo - Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | Flame Biosciences | 2021-08-25 | 2022-01-11 |
Carcinoma, Non-Small-Cell Lung (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
Nivolumab (1)
United States (1)
Cassandra Choe-Juliak, MD (2) · Matthew Galsky, MD (1) · Sumanta Kumar Pal, MD (1) · Swarna Yadlapalli, MD (1)